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Abstract
Background: The emergence and prevalence of multidrug resistant (MDR) pathogenic bacteria poses a serious
threat to human and animal health globally. Nosocomial infections and common ailments such as pneumonia,
wound, urinary tract, and bloodstream infections are becoming more challenging to treat due to the rapid spread
of MDR pathogenic bacteria. According to recent reports by the World Health Organization (WHO) and Centers for
Disease Control and Prevention (CDC), there is an unprecedented increase in the occurrence of MDR infections
worldwide. The rise in these infections has generated an economic strain worldwide, prompting the WHO to
endorse a global action plan to improve awareness and understanding of antimicrobial resistance. This health crisis
necessitates an immediate action to target the underlying mechanisms of drug resistance in bacteria.
Research: The advent of new bacterial genome engineering and synthetic biology (SB) tools is providing
promising diagnostic and treatment plans to monitor and treat widespread recalcitrant bacterial infections. Key
advances in genetic engineering approaches can successfully aid in targeting and editing pathogenic bacterial
genomes for understanding and mitigating drug resistance mechanisms. In this review, we discuss the application
of specific genome engineering and SB methods such as recombineering, clustered regularly interspaced short
palindromic repeats (CRISPR), and bacterial cell-cell signaling mechanisms for pathogen targeting. The utility of
these tools in developing antibacterial strategies such as novel antibiotic production, phage therapy, diagnostics
and vaccine production to name a few, are also highlighted.
Conclusions: The prevalent use of antibiotics and the spread of MDR bacteria raise the prospect of a post-
antibiotic era, which underscores the need for developing novel therapeutics to target MDR pathogens. The
development of enabling SB technologies offers promising solutions to deliver safe and effective antibacterial
therapies.
Keywords: Synthetic Biology (SB), Multidrug resistant (MDR) pathogens, Antibiotic resistance, Genome engineering,
Antibacterial, Quorum sensing, Gene circuits, Pathogenesis, Recombineering, Targetron
Background
The emergence of multidrug resistant (MDR) pathogenic
organisms has become an important national and global
health challenge. Importantly, the evolution of bacterial
MDR pathogens is rampant and needs immediate coun-
termeasures to limit lasting damage. According to the
World Health Organization’s (WHO) report in 2014 on
global surveillance of antimicrobial resistance, the in-
creased rise in MDR pathogenic bacteria is putting at
risk the ability to treat common ailments such as urinary
tract infections, pneumonia and bloodstream infections
globally, that were readily treatable for decades. In 2015,
the 68th World Health Assembly has endorsed a global
action plan to improve awareness and understanding of
antimicrobial resistance [1]. This plan calls for the devel-
opment of new medicines, diagnostic tools, vaccines and
other interventions to ensure continued treatment and
prevention of infectious diseases caused by bacteria.
Therefore, there is an urgent need for understanding
drug resistance mechanisms in MDR pathogens and tar-
geting these mechanisms (e.g., antibiotic target site mu-
tation, efflux pump for antibiotic expulsion, etc.) to
tackle these pathogens. In addition, identification of
novel and improved therapeutic small molecules and
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metabolic engineering for the production of these small
molecules is another approach to assuage drug-
resistance in MDR pathogens.
Recent advancements in synthetic biology (SB) have en-
abled the development of novel genome engineering tools
for the manipulation of microbial genomes for various
biotechnological and biomedical applications [2–6]. SB of-
fers a novel platform to bridge the gap between basic and
translational research and has the potential for providing
innovative solutions to combat infectious agents. SB is an
emerging field which combines engineering principles and
biological parts to design novel, modular and tunable gene
products or genetic circuits for modification of existing
biological systems. In addition to building gene circuits
for desired cellular function or metabolic engineering,
there is a growing interest among synthetic biologists to
develop microbial genome engineering tools. Precise
changes in the bacterial genome have resulted in the cre-
ation of useful biological traits in engineered strains. The
marriage of genome engineering tools and SB has further
enabled the use of engineered bacteria to address some of
the global challenges spanning renewable energy to global
health. In particular, the recent advances in bacterial
genome engineering methods that can target broad range
of bacterial hosts has opened new avenues for fighting
bacterial infections [7, 8]. The development of new SB
tools should pave the way for developing novel approaches
to address the imminent threat with antibiotic resistance
in bacteria.
SB applications in bacteria have broadly ranged from
building small gene circuits for a desired gene/pathway
function to engineering the whole genome [9–12]. A
number of investigations employing SB have also offered
insights into antibiotic resistance mechanisms. For in-
stance, to delineate the mechanism of resistance to a
particular antibiotic, lethal concentrations of antibiotic
triclosan was used in Escherichia coli to identify the gene
candidates that were involved in triclosan resistance
[13]. An overexpressed genomic library was generated in
triclosan enriched media and using a DNA microarray,
the genes that enabled the growth of E. coli in the pres-
ence of triclosan were identified and validated by overex-
pressing the candidate gene in bacteria [14]. Unlike
traditional methods, which involve genome sequencing
to identify potential genes that confer antibiotic resist-
ance, this approach utilized genome libraries cloned into
plasmids for expression in bacteria and enrichment in
the presence of antibiotic. Such SB approach allows for
genome wide screening and identification of genes as
well as the effect of overexpression of these genes on
cellular fitness. This is particularly useful for under-
standing the complex mechanisms of antibiotic resist-
ance and for identifying one or multiple gene targets
that lead to resistance. Similarly, SOS response systems
in E. coli subjected to other antibiotics have been exam-
ined by building gene circuits in E. coli to study DNA
damage and to understand the role of these systems in
antibiotic resistance [15].
Minimal bacterial genomes have been synthesized
using top-down and bottom-up approaches for identify-
ing the essential genes in bacteria (E. coli, Pseudomonas
putida, Mycoplasma) for potential therapeutic targeting
[16–18]. The growth potential and the impact of SB in
countering antibiotic resistance are clearly evident from
these examples. The focus of this review is to highlight
the applications of bacterial genome engineering and
synthetic biology tools in targeting emergent bacterial
pathogens and further discuss the utility of SB in advan-
cing novel antibacterial therapeutics.
Main text
Genome engineering tools and their applications for
countering bacterial infections
A number of methods have been developed for engin-
eering bacterial genomes with varying degrees of effi-
ciency, specificity and broad host applicability [19]. Most
often, the bacterial genome editing is carried out to
knock-out genes, knock-in genes or introduce mutations
in the bacterial genome. Though most of these methods
were developed in E. coli, in the last decade there has
been a rapid development and expansion of these tools
to a broad range of bacterial hosts (Fig. 1a). Noteworthy
is the tractability of these engineering tools in other
pathogenic bacteria, paving the way for exploration and
understanding of these pathogens for combating bacter-
ial infections. A number of useful reviews have also de-
tailed the principles and techniques of bacterial genome
engineering tools [7, 8]. The most common tools that
are currently being utilized for genome engineering of
pathogenic bacteria are summarized in Table 1 and their
potential applications in countering bacterial infections
are discussed below.
Insight into bacterial virulence, resistance mechanism and
biomolecular targets
Bacterial chromosomal modifications have greatly aided
in better comprehension of bacterial pathogenesis and
virulence mechanisms. Among the genome engineering
methods, the utilization of the λ-Red recombinase sys-
tem for insertions, deletions or point mutations of the
genome has been very popular. Pioneered by Murphy
[20] and later modified by Datsenko and Wanner [21],
this method involves the introduction of single- or
double-stranded DNA with chromosomal homology re-
gions for recombination [22]. Since its conception, this
editing strategy has been made more efficient by modifi-
cations to the method developed by Wanner [23–25].
This has also been readily adapted to pathogenic
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Fig. 1 a) Schematic of genome engineering tools developed in E. coli that have been expanded to broad bacterial hosts b) Multiplexed
Automated Genomic Engineering (MAGE) for modifying bacteria at multiple genomic loci
Table 1 Tools available in pathogenic Gram-negative and Gram-positive bacteria for genome modification
Engineering tool Methodology Engineered pathogenic strains
Recombineering Homologous recombination of linear
DNA utilizing λ-Red enzymes Gam,
Exo and Bet
Salmonella enterica [26] a
Escherichia coli [23] a
Pseudomonas aeruginosa [29] a
Streptomyces coelicolor [28] b
Shigella dysenteriae [50] a




Targetrons Retrohoming of Mobile Group II Introns by
reverse splicing and insertion in genome
Clostridium perfringens [38] b
Vibrio Cholera [78] a




Delivery of CRISPR genes and RNA guides
for sequence specific antimicrobials
Carbapenem-resistant Enterobacteriaceae
Enterohemorrhagic Escherichia coli [55] a
Antisense RNA Post-transcriptional gene silencing Staphylococcus aureus [81] b
Streptomyces coelicolor [82] b
aGram-negative pathogens, b Gram-positive bacteria
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bacterial strains for investigating the roles of genes in
pathogenesis [23, 26–29]. Pseudomonas aeruginosa, an
opportunistic pathogen that causes nosocomial infection
and chronic infections of cystic fibrosis lungs, utilizes
two major quorum sensing systems LasR/LasI and RhlR/
RhlI for orchestrating the production of virulence factors
and biofilm formation [30]. To understand their roles in
P. aeruginosa virulence, λ-Red recombination was suc-
cessfully used to generate ΔlasR mutant and ΔlasR/
ΔrhlR double mutant P. aeruginosa strains to delineate
their functions [31]. Using Caenorhabditis elegans 24h
fast-kill infection assay, it was shown that C. elegans was
more rapidly killed by wild-type and ΔlasR mutant com-
pared to the ΔrhlR mutant or ΔlasR/ΔrhlR double mu-
tant strains, indicating that RhlR function is important
for virulence. The authors further identified a small mol-
ecule called meta-bromo-thiolactone (mBTL), an analog
of N-acyl-L-homoserine lactone (AHL), a native P. aeru-
ginosa cell-cell signaling molecule, that was shown to at-
tenuate pyocyanin and biofilm production in the wild-
type strain. To identify if RhlR or LasR receptor is the
molecular target for mBTL, λ-Red recombination system
was used to generate ΔlasR, and ΔlasR/ΔrhlR double
mutants to demonstrate that RhlR is the relevant in vivo
target of mBTL.
One of the key adaptions of Salmonella enterica serovar
typhirium, a pathogen that causes typhoid in humans, is
its ability to survive inside host phagocytes. Macrophages
express inducible nitric oxide (NO) synthase (iNOS) in re-
sponse to lipid A, fimbriae and porins that decorate the
Salmonella envelope. It has previously been demonstrated
that NO produced as an innate response by macrophages
can impact amino acid biosynthesis in Salmonella by tar-
geting DksA. DksA is a key RNA polymerase regulatory
protein in Salmonella, which has been implicated in the
bacterium’s resistance. To determine if DksA is respon-
sible for the antinitrosative defenses in Salmonella,
Henard and Vazquez-Torres generated a dksA mutant
using λ-Red recombination [32, 33]. They determined that
ΔdksA mutant Salmonella strains are hypersusceptible to
the bacteriostatic effects of NO and were noticeably atten-
uated in its infectivity as shown in a murine model of
acute systemic infection.
In order to make genome editing high-throughput, a
recombineering method called Multiplex Automated
Genome Engineering (MAGE) has been developed re-
cently to replace the conventional λ-Red recombinase
based recombineering method (Fig. 1b). This method
employs λ-Red recombinase system and a pool of oligos
to rapidly introduce simultaneous modifications in the
E. coli genome within days [34]. Further improvements
to this method, designated pORTMAGE (portable
MAGE) have been made and extended to clinically rele-
vant strains such as Salmonella enterica [35]. Using
pORTMAGE, ten antibiotic resistance mutations were
introduced simultaneously in the genome of S. enterica
and E. coli to study the extent of conservation of mo-
lecular mechanisms of antibiotic resistance amongst
these bacteria.
For bacteria that are intractable to common engineer-
ing methods such as the λ-Red recombinase system, mo-
bile group II introns have been utilized for site specific
editing of the genome. Mobile group II introns are bac-
terial retrotransposons that contain an intron RNA and
an intron-encoded reverse transcriptase. The mobile
group II introns are ribozymes that can insert into spe-
cific targets by the process of retrohoming [36]. Using
predictive algorithms, the intron RNA can be re-
designed to form a ‘targetron’, such that a target DNA
site of choice can be edited. This method has been
adapted to a number of pathogenic strains for under-
standing mechanisms of virulence [37]. For several med-
ically relevant Clostridium species which are recalcitrant
to recombinations, a targetron based method named
ClosTron technology has been developed for successful
genome editing [38]. In one example, ClosTron technol-
ogy was used for site-directed mutagenesis of a germin-
ation specific protease called CspC in Clostridium
difficile, a causative agent of foodborne infection and
diarrhea. This study helped determine the role of CspC
in host bile acid recognition for in vivo germination and
disease establishment [39].
In another example, the targetron technology was used
in studying virulence mechanism in Pasteurella multo-
cida, an animal pathogen that causes fowl cholera in
wild birds and poultry, hemorrhagic septicemia in ungu-
lates and atrophic rhinitis in swine. The polysaccharide
capsule that is composed of hyaluronic acid is a major
virulence factor. To investigate the mechanism of cap-
sule formation and validate the role of global transcrip-
tional regulator Fis in capsule formation, Steen and
coworkers used the targetron technology in Pasteurella
to generate Fis mutants [40]. They determined that not
only is functional Fis protein required for capsule forma-
tion, but it is also required for regulation of number of
virulence genes.
Production of novel antibiotics
The rate at which bacteria are developing resistance to
existing antibiotics is alarming and warrants our imme-
diate attention to the development of novel antibiotics
for combatting bacterial pathogens. Typically, antibiotics
are naturally derived small molecules that are produced
by genetically encoded pathways. They represent a rich
source of chemical diversity and are produced by an
array of microorganisms. The use of genome editing
tools to engineer new biosynthetic pathways in microbial
hosts is proving to be an ideal strategy for production of
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novel antibiotics [41]. In one instance, Eustaquio and
co-workers employed the λ-Red recombinase method-
ology to inactivate clo-hal and cloz genes in the biosyn-
thetic gene cluster which produces the antibiotic
clorobiocin, a bacterial DNA gyrase inhibitor. The mu-
tated cosmid bearing the inactivated clo-hal cassette or
cloZ gene was introduced in S. roseochromogenes to
study the functional role of these genes in chlorination
of the molecule. Furthermore, this strain was then used
for producing an analog of clorobiocin, which has a me-
thyl group instead of chlorine substitution and showed
reduced antibiotic potency [42].
The λ-Red recombinase based recombineering method
has also been applied for combinatorial biosynthesis of
daptomycin (Cubicin), an antibiotic approved in the US
for the treatment of skin infections caused by Gram-
positive Staphylococcus aureus [43]. The antibiotic also
has potent in vitro bactericidal activity against methicillin
resistant S. aureus (MRSA), penicillin-resistant Streptococ-
cus pneumoniae (PRSP), vancomycin-resistant enterococci
(VRE), and vancomycin-resistant S. aureus (VRSA) [44].
With the emergence of bacterial resistance to this anti-
biotic, there has been an interest to make second gener-
ation derivatives of daptomycin. Using a novel approach,
the λ-Red recombinase methodology has been used for
exchanging multiple modules in the subunits of the nonri-
bosomal peptide synthetase (NRPS) in the daptomycin
biosynthetic pathway using E. coli as a heterologous host
[45]. The combinatorial biosynthesis approach was used
to generate a library of novel lipopeptides with modifica-
tions of the core peptide, of which some compounds were
as active as daptomycin. The above examples illustrate the
huge potential of bacterial genome engineering tools in
biosynthesis of novel antibiotics.
Attenuated vaccine strain development
One of the effective strategies to prevent infections is the
use of vaccination, which establishes an immunological
memory of a foreign agent by triggering the body’s innate
immune response. Inactivated or attenuated vaccines from
the actual pathogen have been successfully used in the
past for defense against bacterial infections. Attenuated
live vaccines are created by decreasing the virulence of the
pathogen to weaken their infection potential without com-
promising the robust host immune response that is re-
quired for protection during future infections that could
be caused by the same pathogen (For example: MTBVAC
against Mycobacterium tuberculosis [46], Ty21a against
Salmonella typhi [47]). There is a growing focus on using
recombinant DNA technology for producing attenuated
strains of pathogenic bacteria [48]. Genome engineering
tools are now being routinely explored for the possibility
of reducing bacterial virulence. For example, Ranallo and
coworkers have successfully demonstrated the extension
of the λ- Red recombination method in Shigella for the
development of live vaccine strains [49]. They utilized
over 13 different isogenic strains to delete genes involved
in various functions such as intracellular growth and
survival (asd), cell to cell spread (virG), invasion (ipaB),
enterotoxic activity (set1A, sen) to name a few. Utilizing a
plaque assay, they determined that the virG deleted strain
reduced plaque formation significantly. In further
virulence testing using the keratoconjuctivitis model
(Sereny test), they found that only the virG deleted strain
was attenuated.
More recently, Salehi and cowokers validated the
utilization of this recombineering technique for the pro-
duction of live attenuated Shigella dysenteriae strain by
deleting ipaD gene [50]. The ipaD is a chaperonin pro-
tein and part of the type III secretion system which se-
cretes invasion plasmid antigen (Ipas) proteins that are
responsible for Shigella penetration and invasion into
epithelial cells. The authors hypothesize that the deletion
of ipaD gene could potentially inhibit secretion of IpaD,
IpaB and IpaC proteins and thereby suppress Shigella
invasion.
The targetron methodology has also been used to
generate candidate vaccine strains in pathogens where
the λ- Red recombination method works poorly. Com-
bining the targetron methodology discussed above and
the well-known Cre-lox recombinase system, a vaccine
strain of the Gram-positive pathogen Staphylococcus
aureus was generated by a novel approach called Gen-
ome Editing via Targetrons and Recombinases (GETR)
[37]. The researchers generated introns that could inte-
grate lox sequences upstream and downstream of the
15-kb Staphylococcus aureus pathogenicity island I
(SaPI-1). The lox sites are specific DNA sequences that
can be targeted by the Cre recombinase enzyme. The ex-
pression of Cre recombinase resulted in Cre-mediated
recombination that deleted the intervening region in the
SaPI-1 leading to the generation of a vaccine strain. The
application of such techniques in clinical isolates of
Staphylococcus can be very useful in generating vaccine
strains for MDR strains for overcoming the antibiotic re-
sistance challenge. Though the safety and efficacy of
these vaccines need to be assessed periodically, the
above examples highlight the power of genome editing
tools for their potential to design live vaccines. Develop-
ment of promising and safe to use vaccines will have
broad applications in preventive healthcare and will be a
stepping stone for the development of oral vaccines in
other pathogenic bacteria [51].
Specificity in pathogen killing and pathogen detection for
diagnosis
Tools adapted from bacteriophage assist in understand-
ing host-pathogen interactions and serve as targeted
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therapeutics [52–54]. Phage can specifically kill virulent
strains of bacteria that bear very close sequence alignment
to harmless strains via the use of the clustered regularly
interspaced short palindromic repeats (CRISPR)/Cas9 sys-
tem. The CRISPR/Cas9 system specifically targets a
DNA sequence for double strand break formation,
resulting in death of the bacteria. Phage can deliver
RNA guides with CRISPR associated proteins (Cas) to
pathogenic bacteria [55, 56].
Towards targeted therapies against pathogenic bacteria,
Citorik et al. have demonstrated sequence specific antimi-
crobials [55], which overcome extremely high genome se-
quence similarity between non-pathogenic and pathogenic
strains by targeting small sequence variations present in the
pathogenic strain. It is possible to harness the ability of
Cas to target specific sequences and differentiate between a
little as one mismatch between target and non-target gen-
omic DNA to kill the pathogenic bacterial population [55].
In the model system of Galleria mellonella larvae, targeted
nucleases showed greater antimicrobial activity than anti-
biotic chloramphenicol. The RNA guided DNA nucleases
targeting of the enterohemorrhagic E. coli intimin virulence
gene and the nuclease activity at this locus proved toxic to
the pathogenic bacteria [55].
In another application of the CRISPR system, Yosef et al.
designed a novel two phage CRSIPR system consisting of
temperate and lytic phage programmed to specifically
sensitize and kill antibiotic resistant bacteria [57]. Initially, ly-
sogenic phage carrying CRISPR machinery was used to tar-
get the antibiotic resistance genes and confer lytic phage
resistance to these cells. The cells became sensitive to anti-
biotic but were resistant to lytic phage. In the second step,
lytic phage was used to kill any remaining antibiotic resistant
cells thus enriching the population of the antibiotic sensitive
cells, which can then be killed with antibiotics. The authors
propose that this strategy can be very useful for treating hos-
pital surfaces or for skin surfaces of medical personnel.
Phage can also serve as diagnostic and detection tools
for infection yet do not require amplification of the host
bacteria as the phage population increases during infec-
tion. As the phage infects specific bacteria, the phage
genomic template becomes enriched in the population
and targeted bacteria can be killed by the phage. A
quantitative PCR following phage infection can indicate
amplification of phage DNA infecting a specific bacteria
[53]. Diagnostic phages exist for highly pathogenic bac-
teria, such as phage phi A1122 for Yersinia pestis, as
well as phage reporter systems for Bacillus anthracis
and Mycobacterium tuberculosis [58].
Application of synthetic biology for targeting bacterial
infections
Key advances in precision genome engineering have re-
sulted in the development of a toolbox that is proving
highly valuable for redesigning microbial genome struc-
ture for useful applications. The bacterial genome engin-
eering strategies discussed in the previous sections
clearly illustrate the utility of these tools in synthetic
biology applications for targeting infectious diseases.
Apart from gene insertions, deletions or mutations for
modification of the genome using engineering tools, one
of the main goals of SB is to build and integrate gene
circuits which process signals within a living cell for a
desired output. Gene circuits have been assembled in
microbes using biological parts or functional units for
various biomedical applications [59, 60]. Modular bio-
logical parts can be connected to develop circuits based
on electrical engineering principles with input and out-
put responses that can be analog or digital. Using this
engineering framework, SB has potential applications in
biofuel production, synthesis of industrial chemicals or
natural product substitutes, biomedical applications or
understanding and countering bacterial infections
(Fig. 2a) [2, 5, 59]. In the following section, we highlight
few examples of regulatory biological components that
have been utilized for biomedical applications focused
on bacterial infections.
Bacterial quorum sensing based circuits
Bacteria effectively sense and respond to environmental
signals as part of their natural survival and proliferation
strategies. SB has harnessed these mechanisms to sense
and respond to clinically relevant signals. The develop-
ment and engineering of bacterial small molecule signal-
ing mechanism based SB circuits for targeting bacterial
pathogens has also been used as a novel approach in de-
sign of circuits.
Bacterial cell population-density dependent behavior
termed quorum sensing (QS) is a highly evolved natural
signaling circuit found in bacteria [60]. It involves small
molecule signal production and sensing by the native
bacterium via their cognate signal receptor that then
modulate the expression of the target genes [60]. Initial
QS SB circuit engineering in bacteria was demonstrated
by Weiss and Knight Jr. [61]. One of the Vibrio fischeri
QS systems relies on a key small molecule signal N-
Acyl-L- homoserine lactone (AHL) for its biolumines-
cence production. In their first SB circuit, AHL synthesis
catalyzed by luxI (AHL synthase) and the AHL signal re-
ceptor luxR were engineered into two separate popula-
tions (A and B populations respectively) of E. coli. When
these strains were cocultivated, it was observed that the
AHL signals produced by E. coli (luxI) (population A)
freely diffused out the cell and bound to its cognate LuxR
receptor in E. coli (luxR) subpopulation (population B).
The activated LuxR-AHL complex in turn activated lux-
I::gfp promoter-reporter fusion resulting in GFP produc-
tion [61]. With this early demonstration, interest in the
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utility of QS circuits in SB has increased in a number of
biomedical applications including diagnostic tools, cancer,
immune diseases, metabolic disorders, infectious disease
therapies, drug production through fermentation, biosens-
ing, etc [62–64].
In an important example, Duan and March showed
that feeding infant mice with engineered probiotic E.
coli to constitutively overexpress Vibrio cholerae QS
signal (S)-3-hydroxytridecan-4-one or Cholerae
autoinducer-1 (CAI-1) that down-regulates biofilm
production substantially increased the mice survival
rate from V. cholerae infections (92% with 8h pre-
treatment) [65] (Fig. 2b). Using a gene circuit, Saeidi et
al. engineered E. coli with P. aeruginosa LasR AHL recep-
tor to sense P. aeruginosa AHL signal N- 3-oxo-
dodeconoyl-L-HSL and auto-regulate the activation of
killing and lysis gene products (E7 lysis protein and Pyocin
S5) that targeted P. aeruginosa [66]. In conjunction with
this design, other QS circuits for pathogen targeting based
on detection, destruction and secretion modules have
been successfully engineered into useful bacteria. For
example, in a proof-of-concept study, pathogen P.
aeruginosa elimination was demonstrated using pro-
grammed E. coli sensing P. aeruginosa QS signal N- 3-oxo-
dodeconoyl-L -HSL and activating the production and
secretion of chimeric lethal protein bacteriocin CoPy [67].
Another example of this modular bacterial QS cir-
cuit engineering was demonstrated by programming
E. coli to seek and kill P. aeruginosa. This system uti-
lized CheZ, a motility promoting protein and two
engineered secrete and kill proteins DNaseI and
MicrocinS that promoted biofilm disruption and le-
thality [68]. Most of these QS circuits essentially tar-
get Gram-negative bacterial circuits and in particular
only the AHL class of QS molecules. There is a great
diversity of QS molecules (non-AHL classes) and
pathways that still remain underexplored for targeting
and can be effectively used for pathogen control.
RNA based circuits
RNA based biological parts called riboregulators are
also gaining attention in SB circuit design due to
their tunable and modular nature. These RNA hair-
pin tools are designed to sequester the ribosome
Fig. 2 a) Synthetic biology circuits can be engineered with desired input and output signals to kill bacterial pathogens; b) Engineering probiotic
bacteria that expresses QS molecule Cholerae autoinducer-1 (CAI-1) to target Vibrio cholerae infection in a mouse model [65]
Krishnamurthy et al. BMC Microbiology  (2016) 16:258 Page 7 of 11
binding site (RBS) upstream of the start site of the
mRNA encoding a gene in order to block translation
[58, 69–72]. In one application of these tools, RNA
switches called “toehold” switches developed by Par-
dee et al. have been used for diagnostic application
for in vitro, cell-free, paper-based devise for sensing
Ebola mRNA and mRNAs of antibiotic resistance
genes [73]. RNA based diagnostic gene network con-
sists of a reporter gene network (gfp, lacZ), where
the RBS is sequestered upstream by the toehold
switch. The gene network and a cell-free coupled
transcription/translation system are freeze dried on a
paper or other porous material and can be activated
by rehydration with the test sample which consists
of the mRNA to be detected. Messenger RNA sen-
sors for antibiotic resistance genes, upon sensing the
target gene, showed significant induction of reporter
gene making this tool highly promising and cost-
effective in the detection and diagnosis of bacterial
infections in clinical samples.
Apart from application in diagnostics, the ability of
fine-tuning gene expression and the modular nature of
riboregulators make them excellent candidates for
chromosomal integrations using existing genome editing
tools for biosynthetic pathway engineering in bacterial
hosts. It is evident from the above examples that genome
engineering and synthetic biology tools in bacteria can
have significant impact on a number of applications for
targeting bacterial infections (Fig. 3).
Conclusions
The integration of engineering principles and biology
in the last decade has opened up new avenues for
development of novel therapeutics in treating dis-
eases. The rapid emergence of bacterial antimicrobial
resistance and limited success in identifying new an-
tibiotics warrants the identification and validation of
novel bacterial drug targets. SB driven genome edit-
ing techniques offer new avenues to pursue bacterial
target identification and present the possibilities for
development of novel antimicrobial therapeutics. The
availability of high-throughput bacterial genome edit-
ing tools coupled with advancement in DNA synthe-
sis technologies provides new opportunities for
metabolic engineering of large gene clusters in mi-
crobial hosts. By rational combination of gene parts,
biosynthesis can be potentially reprogrammed for
generation of novel small molecules for therapeutic
purposes [48]. This is further facilitated by in silico
whole genome mining and software algorithms that
predict the gene clusters which can be used in bio-
synthetic pathway engineering for production of
novel antibiotics [48, 74]. This offers huge potential
for combinatorial biosynthesis of natural product an-
alogs for the discovery of novel antibiotics, as in the
example of antibiotic daptomycin described in the
earlier section [41].
In addition to antibiotics, development of alternative
treatment options employing bacteriophage and pro-
biotic bacterial engineering for pathogen targeting and
destruction are critical for the fight against infections,
including the drug-resistant bacterial pathogens. Ad-
vances in computational gene circuit design coupled
with improvements in large scale DNA synthesis heralds
a new era of SB based therapeutic approaches. It is now
possible to design whole bacterial genomes from synthe-
sized components. Viewing genetic code as an analog to
computer software, one can then “boot” the synthetic
genome in a compatible cellular environment [75].
Additionally, computational design of synthetic circuits
Fig. 3 Multipronged use of SB and genome engineering tools to counter bacterial infections
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will be highly useful for predicting the optimal combin-
ation of synthetic parts for a desired cellular function.
Recently, Voigt and coworkers developed the Cello soft-
ware, which allows a user to program a desired circuit
function in E. coli and compile the code into a DNA
sequence for synthesis [76]. Computer-aided design
(CAD), high-throughput DNA synthesis and advanced
genome editing techniques will prove highly valuable for
generating re-programmed bacterial strains for thera-
peutic applications. The combination of advanced com-
putational methods for predictive SB systems, and rapid
progress in technologies for efficient large scale DNA
synthesis as well as high-throughput, automated genome
engineering such as MAGE, pORTMAGE indicates that
SB has immense potential to deliver novel solutions for
pathogen control.
Genetically modified bacteria offer great hope for
finding novel solutions to detect and treat infections.
However, it is also imperative to periodically asses the
biosafety of these organisms to avoid accidental release
of synthetic bacteria generated in some of these applica-
tions. To address this concern, two engineered safeguard
systems called the ‘Deadman’ and ‘Passcode’ kill switches
have been developed by Collins and colleagues in E. coli
[77]. These switches are based on circuits that need
specific input(s) of small-molecules for cell survival. In
the absence or presence of the specific molecules, toxin
gene expression is activated leading to cell death. The
kill switch circuit designs can potentially be incorporated
in a broad range of bacterial hosts to ensure safe hand-
ling of these modified organisms. It is clearly evident
from the above examples that SB is bridging the gap be-
tween basic and translational research. It is expected
that with continuous technological advances in this field
and with development of new programmable biological
tools, SB has enormous potential to develop biomedical
therapies to prevent and treat diseases caused by bacter-
ial infections.
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